New York Launches First State-Led Cannabis Study on CBD, THC, and IBD

A State Regulatory Agency Does Something No State Has Done Before

The New York State Office of Cannabis Management (OCM) just crossed a threshold that separates it from every other cannabis regulator in the country: it designed and launched its own clinical research study. Announced in May 2026, the pilot observational study examines how oral doses of CBD and THC affect quality of life in adults living with moderate inflammatory bowel disease.

The study is titled "A Pilot Prospective Observational Study to Assess the Effects of Cannabidiol (CBD) and Delta-9-Tetrahydrocannabinol (THC) on Inflammatory Bowel Disease Symptoms," and it represents the first time a state cannabis regulatory agency has moved from simply regulating cannabis to actively generating clinical evidence about it.

Why IBD — and Why Now

Inflammatory bowel disease encompasses two chronic conditions — Crohn's disease and ulcerative colitis — that cause inflammation of the gastrointestinal tract. Together, they affect an estimated 3.1 million adults in the United States, according to the Centers for Disease Control and Prevention. Symptoms include severe abdominal pain, persistent diarrhea, rectal bleeding, fatigue, and unintended weight loss.

Standard treatments include aminosalicylates, corticosteroids, immunomodulators, and biologics. These therapies help many patients, but a substantial subset — those with moderate disease that does not respond fully to prescribed treatment — remain symptomatic. It is precisely this population that the OCM study targets: patients whose symptoms are "still not well managed with a prescribed treatment regimen."

The timing is informed by a growing body of anecdotal and preliminary evidence. A separate study published earlier in 2026 found that 87.5% of IBD patients already using CBD reported symptom relief. The endocannabinoid system plays a documented role in gut inflammation, motility, and visceral pain perception, making the GI tract a biologically plausible target for cannabinoid therapy.

Study Design and Methodology

The OCM study is observational, not interventional. This distinction matters: participants are not randomly assigned to receive cannabis or a placebo. Instead, researchers will observe IBD patients who are already using — or who choose to begin using — oral CBD and THC products available through New York's regulated medical cannabis program.

Key design elements include:

Patient Population

Adults with clinically confirmed moderate IBD whose symptoms are inadequately controlled by their current treatment regimen. Participants must be enrolled in New York's medical cannabis program or willing to enroll.

Endpoints

The primary outcome is change in quality of life, measured through validated patient-reported outcome tools. Secondary endpoints are expected to include symptom severity scores, frequency of flare-ups, and any changes in conventional medication use.

Data Collection

The study will collect data at multiple time points, allowing researchers to track changes in symptoms and quality of life over a sustained period rather than relying on a single snapshot.

Cannabinoid Products

Participants will use commercially available oral cannabis products — capsules, tinctures, or other oral formats — containing CBD and THC in ratios available through licensed dispensaries. This pragmatic approach ensures that findings are directly applicable to real-world patient experiences.

From Anecdotal to Data-Driven

Dr. Nakesha Abel, OCM's Director of Scientific Programs and Research, framed the study's significance in terms that underscore the cannabis industry's biggest evidence gap: "Research like this helps move the conversation about cannabis from anecdotal experiences to measurable, data-driven patient outcomes."

That gap has been one of the central tensions in medical cannabis for decades. Millions of patients use cannabis for various conditions, and surveys consistently show high satisfaction rates. But the controlled clinical data that physicians, insurers, and regulators need to make evidence-based decisions has lagged behind patient adoption — in large part because Schedule I classification made federally funded research extraordinarily difficult.

The recent rescheduling of state-licensed medical cannabis to Schedule III, effective April 22, 2026, loosens some of those research barriers. While the OCM study was likely designed before the rescheduling order, the new regulatory environment makes it easier for other states to follow New York's lead.

What Existing Research Shows About Cannabis and IBD

The OCM study does not emerge from a scientific vacuum. Here is what peer-reviewed research has established so far:

The Endocannabinoid System and the Gut

CB1 and CB2 receptors are widely expressed throughout the gastrointestinal tract. The endocannabinoid system modulates gut motility, visceral sensation, and inflammation — all processes disrupted in IBD. Preclinical studies have consistently shown that cannabinoid agonists reduce inflammation in animal models of colitis.

CBD's Anti-Inflammatory Mechanisms

CBD has demonstrated anti-inflammatory properties through multiple pathways, including suppression of pro-inflammatory cytokines, modulation of oxidative stress, and interaction with TRPV1 receptors involved in visceral pain signaling. A 2026 study found that CBD reduced breast cancer cell viability through oxidative stress and mitochondrial dysfunction — mechanisms with potential relevance to other inflammatory conditions.

THC and Symptom Relief

THC's analgesic and appetite-stimulating properties address two of the most debilitating symptoms of IBD: chronic abdominal pain and weight loss from reduced food intake. Small clinical trials and observational studies have found that cannabis use is associated with improved appetite, reduced pain scores, and better subjective well-being in IBD patients.

The 87.5% Relief Finding

A study published in April 2026 surveyed IBD patients using CBD and found that 87.5% reported symptom improvement. While the finding is striking, it comes from a survey rather than a controlled trial, which is exactly the type of evidence gap the OCM study aims to address.

How This Study Differs from Federal Research

Federal cannabis research has historically operated through a narrow pipeline: the National Institute on Drug Abuse (NIDA) controlled the sole legal supply of research-grade cannabis, and investigators needed DEA Schedule I researcher registrations and IRB approvals before they could begin studying the plant.

The OCM study bypasses several of these bottlenecks by leveraging New York's existing medical cannabis infrastructure. Participants use commercially available products from state-licensed dispensaries rather than NIDA-supplied cannabis, which has been widely criticized for its poor quality and lack of resemblance to products patients actually consume.

This pragmatic approach has a scientific advantage: the findings will reflect real-world patient behavior with real-world products. But it also has limitations — without a control group receiving a placebo, the study cannot establish causation, only correlation. Observational data can show that IBD patients using CBD and THC experience improved quality of life, but cannot definitively prove that the cannabinoids caused the improvement.

Implications for Other States

If the OCM study produces positive findings, it could become a model for state cannabis agencies nationwide. Currently, most state regulators view their role as licensing and enforcement. New York is making a case that regulators also have a responsibility to generate the evidence that patients, physicians, and policymakers need to make informed decisions about medical cannabis.

Several states with mature medical cannabis programs — Illinois, Massachusetts, Maryland, and Colorado among them — have the infrastructure and patient populations to conduct similar studies. The question is whether they have the institutional will and the research expertise within their regulatory agencies to follow suit.

What Patients Should Know

For IBD patients in New York considering participation, a few practical points:

Enrollment requires being part of New York's medical cannabis program, which involves certification from a registered healthcare provider. The study is observational — participants are not required to change their current treatment regimen, and their conventional IBD medications continue as prescribed.

The study does not provide free cannabis products. Participants will purchase products through licensed dispensaries at standard pricing, though the specific product recommendations (ratios, dosages, formats) will be guided by the study protocol.

Results from this pilot study will not be available immediately. Observational studies typically require months of data collection followed by statistical analysis and peer review. Preliminary findings might emerge by late 2026 or early 2027, with published results following thereafter.

For more information, patients can visit cannabis.ny.gov to learn about the study and New York's medical cannabis program.